News

Researchers demonstrates feasibility, the long-term therapeutic effectiveness and the safety of S100A1 gene therapy in a large animal model of heart failure.

The study analyze the long-term outcomes of women who received their own stem cells that had undergone purification process.

The scientists identified a protein called Fgf as the controlling factor which determines whether developing heart cells become heart muscle or blood vessels.

The results came from research in rabbits, published July 19 in the journal Molecular Therapy.

By fusing Oct4 and MyoD proteins researchers succeeded in “powering up” the stem cell regulator, which improve the efficiency and purity of reprogrammed iPS cells.

Development of novel nanoparticles that have optimal chemical and physical properties for effective intracellular delivery of RNAi therapeutics.

USC scientists proved that oncogenes change normal cells into stem-like cells, paving the way to a safer and more practical approach to treating diseases with stem cell therapy.

A molecular technique originally developed at the University of North Carolina at Chapel Hill has taken one step closer to becoming a treatment for the devastating genetic disease Duchenne muscular dystrophy.

C5-LIMS by SoftwarePoint has been chosen by a major regional public health care authority in Northern Europe.

New data describes new approach for systemic delivery of RNAi therapeutics using combinations of lipid-like materials called "lipidoids.”